Biogen Idec enters $380M deal on AD Abs with Neurimmune

26 November 2007

US drugmaker Biogen Idec and Switzerland's Neurimmune Therapeutics AG have entered into an agreement for the worldwide development and commercialization of novel, fully-human antibodies for the treatment of Alzheimer's disease. The alliance will focus on the development of antibodies that bind to amyloid-beta, a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in AD patients. Neurimmune will conduct research to identify potential antibodies using its Reverse Translational Medicine platform. Biogen will be responsible for the development and commercialization of all products. Neurimmune could receive an aggregate of $380.0 million in upfront and success-based milestone payments, as well as a royalty on net sales of any products, the firm added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK